Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
The Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) news page on Stock Titan aggregates company announcements, scientific conference updates and regulatory disclosures related to its Actinium-225 targeted radiotherapy programs. Actinium regularly issues press releases detailing preclinical and clinical data, corporate events and participation in oncology meetings, offering investors and observers insight into the evolution of its pipeline.
Recent news has focused heavily on ATNM-400, the company’s first-in-class, multi-indication Ac-225 antibody radioconjugate. Actinium has reported preclinical data for ATNM-400 in metastatic castration-resistant prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer, including models resistant to standard-of-care therapies such as enzalutamide, 177Lu-PSMA-617, osimertinib, tamoxifen and trastuzumab. Releases describe superior tumor growth inhibition versus several approved agents, durable tumor control, and synergistic effects when ATNM-400 is combined with ARPIs or EGFR inhibitors.
News items also cover Actimab-A, a CD33-targeting Ac-225 therapeutic for acute myeloid leukemia, including its planned pivotal Phase 2/3 trial and a Cooperative Research and Development Agreement with the National Cancer Institute. Additional updates describe Iomab-ACT and Iomab-B in conditioning for bone marrow transplant and cell or gene therapies, as well as Actinium’s broader research efforts in solid tumors.
Visitors to this page can review earnings‑independent scientific updates, conference abstracts and corporate communications that outline Actinium’s development strategy, preclinical results and governance milestones such as annual meeting outcomes. For anyone tracking ATNM as an oncology development story, this news feed provides a centralized view of how the company portrays progress across its Ac‑225 radiotherapy platform.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced several key senior leadership appointments aimed at advancing its growth strategy. Arun Swaminathan, Ph.D., has been appointed as Chief Business and Commercial Officer, while Paul Diamond, Ph.D., joins as Vice President, Patent and Legal Counsel. Avinash Desai, M.D., has been promoted to Chief Medical Officer. These leaders together bring over 50 years of experience in biopharmaceuticals, enhancing Actinium's focus on its pipeline, particularly the recently completed Phase 3 SIERRA trial for Iomab-B.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced its participation in four upcoming investor conferences, highlighting its pivotal Phase 3 trial for Iomab-B and upcoming milestones from its targeted radiotherapy pipeline. The conferences are scheduled from September 27 to October 13, 2021. CEO Sandesh Seth emphasized the strong momentum as the company approaches significant data updates in the fourth quarter. Actinium specializes in targeted radiotherapies aimed at treating patients with unmet needs, focusing on improving outcomes through innovative therapies.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has completed enrollment in the pivotal Phase 3 SIERRA trial for Iomab-B, aimed at treating patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial, involving 150 patients across 24 centers in the U.S. and Canada, assesses the efficacy of Iomab-B in providing Bone Marrow Transplant (BMT) access. Actinium plans to present data updates in Q4 2021 and topline results in mid-2022 to support a Biologics License Application (BLA) for Iomab-B.
Actinium Pharmaceuticals (NYSE: ATNM) announced its inclusion in the Russell Microcap® Index effective June 28, 2021. This membership, determined by market-cap rankings, will last for one year and grants Actinium access to associated growth and value style indexes. The Russell indexes are critical benchmarks for investment managers, with approximately $10.6 trillion in assets linked to them. As a clinical-stage biopharmaceutical company, Actinium focuses on developing innovative therapies, notably its lead candidate I-131 apamistamab, which is under study for conditioning before bone marrow transplants.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced the enhancement of its intellectual property portfolio for its lead candidate, Iomab-B, with patents granted in the EU and Japan. These patents, covering the composition and administration methods of Iomab-B, are expected to be valid through 2036 and 2037. Actinium aims to leverage its patents for aggressive development in targeted conditioning, particularly for bone marrow transplants and cell therapies. The company holds multiple patents globally and enjoys orphan drug designation for Iomab-B, potentially providing market exclusivity.
Actinium Pharmaceuticals (NYSE: ATNM) presented promising data from its pivotal Phase 3 SIERRA trial for Iomab-B at the 2021 SNMMI Annual Meeting. Iomab-B, a radiotherapy targeting CD45, aims to enable potentially curative bone marrow transplant (BMT) for patients with relapsed or refractory acute myeloid leukemia (AML) aged 55 and above. The trial showed a remarkable 100% BMT and engraftment rate in the Iomab-B group, while only 18% in the control arm. With 75% patient enrollment completed, the results highlight Iomab-B's potential to transform treatment outcomes in this challenging patient population.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presented safety data from the Phase 3 SIERRA trial of Iomab-B for relapsed or refractory Acute Myeloid Leukemia at the 2021 SNMMI Annual Meeting. The study involved 113 patients, demonstrating lower rates of sepsis, febrile neutropenia, mucositis, and non-relapse transplant-related mortality compared to traditional therapies. Iomab-B's targeted delivery system aims to minimize side effects while preparing patients for bone marrow transplants. With 75% enrollment complete, Actinium anticipates further data presentations in the future.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced acceptance of three abstracts from its pivotal Phase 3 SIERRA trial for Iomab-B at the SNMMI 2021 Annual Meeting, scheduled for June 11-14. Iomab-B targets conditioning prior to bone marrow transplantation for patients aged 55 and over with relapsed or refractory acute myeloid leukemia. The trial reports a 25%, 50%, and 75% enrollment, showcasing Iomab-B's potential as a best-in-class treatment with low transplant-related mortality. The findings emphasize the significance of Iomab-B in improving BMT outcomes.
Actinium Pharmaceuticals (NYSE: ATNM) will present its Iomab-ACT program at the Cell & Gene Meeting on the Mediterranean from April 6-9, 2021. Iomab-ACT is a lower-dose radiation treatment aimed at achieving lymphodepletion before CAR-T therapies and gene therapies. The company collaborates with Memorial Sloan Kettering Cancer Center for a pioneering trial targeting CD19 CAR T-cell therapy, and with UC Davis for anti-HIV stem cell gene therapy. Actinium continues to advance its clinical pipeline focusing on improving patient outcomes in hematologic malignancies.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced the completion of patient enrollment in the second dose cohort of the Phase 1 portion of its Actimab-A and venetoclax combination trial for relapsed/refractory Acute Myeloid Leukemia (r/r AML). This trial aims to determine the maximum tolerable dose of Actimab-A before progressing to Phase 2. Initial results from the first dose cohort indicated significant patient responses, with one complete remission and another partial response noted. Actinium plans to present further data in the latter half of 2021.